Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.

Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease

Open access
Rivero-Ríos, Pilar, Madero-Pérez,, Jesús, Fernández, Belén, Hilfiker, Sabine · 2016 · Current Neuropharmacology

Abstract

Autophagy is a cellular quality control mechanism crucial for neuronal homeostasis. Defects in autophagy are critically associated with mechanisms underlying Parkinson's disease (PD), a common and debilitating neurodegenerative disorder. Autophagic dysfunction in PD can occur at several stages of the autophagy/lysosomal degradative machinery, contributing to the formation of intracellular protein aggregates and eventual neuronal cell death. Therefore, autophagy inducers may comprise a promising new therapeutic approach to combat neurodegeneration in PD. Several currently available FDA-approved drugs have been shown to enhance autophagy, which may allow for their repurposing for use in novel clinical conditions including PD. This review summarizes our current knowledge of deficits in the autophagy/lysosomal degradation pathways associated with PD, and highlight current approaches which target this pathway as possible means towards novel therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x13666151030103027

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) The three types of autophagy and their pathways. Macroautophagy (often referred to as just autophagy) is the most common pathway. Autophagy induction can be triggered by either mTORC1-dependent or -independent means, causing activation of the ULK protein complex, comprised of Atg13, ULK1/2 and FIP200, which assembles at the isolation membrane and causes activation of the Vps34-Beclin 1 complex at the PAS. Upon nucleation, phagophore formation and elongation is mediated by Atg9. This requires the Atg5-Atg12-Atg16L1 complex, which mediates the conjugation of phosphatidylethanolamine to LC3-I, generating LC3-II which becomes anchored on the surface of the nascent autophagosome. Upon completion, autophagosomes undergo microtubule-dependent transport to fuse with either late endosomes (to form amphisomes), or with lysosomes (to form autolysosomes), and contents are degraded in the acid environment with the help of acid hydrolases. During chaperone-mediated autophagy (CMA), substrates bearing a KFERQ-like motif are recognized by a chaperone/co-chaperone complex in the cytosol. This complex transfers the protein to the surface of the lysosomal membrane, where the binding to the cytosolic tail of the LAMP2A receptor takes place. Binding causes LAMP2A multimerization and substrate unfolding, followed by the translocation of the protein across the lysosomal membrane and its subsequent degradation by lysosomal hydrolases. Microautophagy is the least understood process, consisting of the direct invagination of the lysosomal membrane to form intraluminal vesicles loaded with cytosolic contents or organelles. Once inside the lysosome, these vesicles and their contents are then degraded. For further details see text.
Fig. (1) The three types of autophagy and their pathways. Macroautophagy (often referred to as just autophagy) is the most common pathway. Autophagy induction can be triggered by either mTORC1-dependent or -independent means, causing activation of the ULK protein complex, comprised of Atg13, ULK1/2 and FIP200, which assembles at the isolation membrane and causes activation of the Vps34-Beclin 1 complex at the PAS. Upon nucleation, phagophore formation and elongation is mediated by Atg9. This requires the Atg5-Atg12-Atg16L1 complex, which mediates the conjugation of phosphatidylethanolamine to LC3-I, generating LC3-II which becomes anchored on the surface of the nascent autophagosome. Upon completion, autophagosomes undergo microtubule-dependent transport to fuse with either late endosomes (to form amphisomes), or with lysosomes (to form autolysosomes), and contents are degraded in the acid environment with the help of acid hydrolases. During chaperone-mediated autophagy (CMA), substrates bearing a KFERQ-like motif are recognized by a chaperone/co-chaperone complex in the cytosol. This complex transfers the protein to the surface of the lysosomal membrane, where the binding to the cytosolic tail of the LAMP2A receptor takes place. Binding causes LAMP2A multimerization and substrate unfolding, followed by the translocation of the protein across the lysosomal membrane and its subsequent degradation by lysosomal hydrolases. Microautophagy is the least understood process, consisting of the direct invagination of the lysosomal membrane to form intraluminal vesicles loaded with cytosolic contents or organelles. Once inside the lysosome, these vesicles and their contents are then degraded. For further details see text.CC BY-NC · PubMed Central
Fig. (2) Effects of α-synuclein and other gene products linked to familial PD at various points along the autophagic pathway. Wildtype α-synuclein seems to interfere with autophagy induction by mislocalizing Atg9. In addition, α-synuclein aggregates can also impair autophagy at a later stage, and mutant α-synuclein can impair CMA. Mutant LRRK2 seems to interfere with autophagic clearance of autophagosomes, and also with CMA. Vps35 seems to interfere with the proper delivery of lysosomal hydrolases, thus causing reduced lysosomal functioning. Mutations in Parkin and PINK1 interfere with proper autophagic clearance of defunct mitochondria, causing a buildup of these organelles and failure to properly meet metabolic demands. Both mutant GBA and ATP13A2 decrease lysosomal degradative capacity. In all cases, this may lead to the toxic buildup of alphα-synuclein, causing further α-synuclein-mediated autophagic impairment and eventual cellular demise. See text for more details.
Fig. (2) Effects of α-synuclein and other gene products linked to familial PD at various points along the autophagic pathway. Wildtype α-synuclein seems to interfere with autophagy induction by mislocalizing Atg9. In addition, α-synuclein aggregates can also impair autophagy at a later stage, and mutant α-synuclein can impair CMA. Mutant LRRK2 seems to interfere with autophagic clearance of autophagosomes, and also with CMA. Vps35 seems to interfere with the proper delivery of lysosomal hydrolases, thus causing reduced lysosomal functioning. Mutations in Parkin and PINK1 interfere with proper autophagic clearance of defunct mitochondria, causing a buildup of these organelles and failure to properly meet metabolic demands. Both mutant GBA and ATP13A2 decrease lysosomal degradative capacity. In all cases, this may lead to the toxic buildup of alphα-synuclein, causing further α-synuclein-mediated autophagic impairment and eventual cellular demise. See text for more details.CC BY-NC · PubMed Central
Fig. (3) Regulation of autophagy by mTOR-dependent and -independent pathways. Rapamycin or its analog CCI-779 inhibit mTORC1, causing activation of the ULK complex and the Vps34-beclin 1 complex to induce autophagy. Autophagy can also be induced upon overexpression of beclin 1, or of a peptide derived from it, respectively. A variety of mTOR-independent means to induce autophagy have been described, which seem to work along a cyclical pathway involving changes in cAMP, inositol signalling and intracellular calcium levels. Increased cAMP levels seem to inhibit autophagy, and blocking adenylate cyclase induces autophagy. cAMP activates PLC, generating IP3, which seems to inhibit autophagy. IP3 causes calcium release from ER stores, and increased intracellular calcium inhibits autophagy. Therefore, decreasing cytosolic calcium levels by blocking calcium release from the ER, or by blocking calcium entry through calcium channels, enhances autophagy. Similarly, decreasing intracellular free inositol or IP3 levels induces autophagy. Calcium also activates calpain, which in turn activates adenylate cyclase through Gsalpha, thereby creating a negative feedback loop resulting in the generation of more IP3, more calcium release from internal stores, and more autophagy inhibition. The precise mechanism(s) by which calcium inhibits autophagy remain unclear, but involve both early steps by inhibiting autophagosome synthesis, as well as late steps by interfering with autophagosome-lysosome fusion. Apart from these pathways, autophagy can also be upregulated by expression of TFEB, causing a coordinated increase in the expression of autophagy-related and lysosomal genes, by spermidine and resveratrol, which cause varied epigenetic changes to enhance autophagic flux, and by LAMP2A, which causes an increase in CMA. For further details see text.
Fig. (3) Regulation of autophagy by mTOR-dependent and -independent pathways. Rapamycin or its analog CCI-779 inhibit mTORC1, causing activation of the ULK complex and the Vps34-beclin 1 complex to induce autophagy. Autophagy can also be induced upon overexpression of beclin 1, or of a peptide derived from it, respectively. A variety of mTOR-independent means to induce autophagy have been described, which seem to work along a cyclical pathway involving changes in cAMP, inositol signalling and intracellular calcium levels. Increased cAMP levels seem to inhibit autophagy, and blocking adenylate cyclase induces autophagy. cAMP activates PLC, generating IP3, which seems to inhibit autophagy. IP3 causes calcium release from ER stores, and increased intracellular calcium inhibits autophagy. Therefore, decreasing cytosolic calcium levels by blocking calcium release from the ER, or by blocking calcium entry through calcium channels, enhances autophagy. Similarly, decreasing intracellular free inositol or IP3 levels induces autophagy. Calcium also activates calpain, which in turn activates adenylate cyclase through Gsalpha, thereby creating a negative feedback loop resulting in the generation of more IP3, more calcium release from internal stores, and more autophagy inhibition. The precise mechanism(s) by which calcium inhibits autophagy remain unclear, but involve both early steps by inhibiting autophagosome synthesis, as well as late steps by interfering with autophagosome-lysosome fusion. Apart from these pathways, autophagy can also be upregulated by expression of TFEB, causing a coordinated increase in the expression of autophagy-related and lysosomal genes, by spermidine and resveratrol, which cause varied epigenetic changes to enhance autophagic flux, and by LAMP2A, which causes an increase in CMA. For further details see text.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 108 references

Research works printed but not linked: 1

  1. [74]Manzoni C. Lewis P.A. Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J. 2013 27 9 3424 3429 10.1096/fj.12-223842 23682122 PMC4194632 · DOI

Cited by

See all 72

Metadata

Authors
Rivero-Ríos, P., Madero-Pérez, Fernández, B., & Hilfiker, S.
Affiliations
Consejo Superior de Investigaciones Científicas (ES)
Corresponding author
Hilfiker, Sabine
Venue
Current Neuropharmacology
Published
2016-03-03
Volume
14
Issue
3
Pages
238-249
ISSN
1570-159X (ISSN-L)
OpenAlex
W2303253494
Cited by
69
References
108
Citations by year
2026: 1 · 2025: 5 · 2024: 5 · 2023: 9 · 2022: 3 · 2021: 10 · 2020: 10 · 2019: 9 · 2018: 5 · 2017: 7 · 2016: 5
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Michael J. Fox Foundation for Parkinson's Research
  • Fundación BBVA
  • Ministerio de Economía y Competitividad (SAF2014-58653-R)
  • Banco Bilbao Vizcaya Argentaria
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Parkinson's disease, autophagy, lysosomal degradation, autophagy inducers, neurodegeneration, protein aggregation, neuronal cell death, drug repurposing, FDA-approved drugs, therapeutic target
MeSH terms
Animals, Antiparkinson Agents, Autophagy, Humans, Lysosomes, Parkinson Disease, Metabolic Networks and Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease. https://app.cochat.ai/papers/10.2174/1570159x13666151030103027
The paper
Rivero-Ríos, P., Madero-Pérez, Fernández, B., & Hilfiker, S. (2016). Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease. Current Neuropharmacology. https://doi.org/10.2174/1570159x13666151030103027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.